N/A
N=18
Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant
Liver Failure
Bottom Line
View on ClinicalTrials.gov: NCT00886262 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcome: Primary: Change in Creatinine Levels — 0.5; 0.55 MG/DL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Vasopressin (Drug); Normal saline placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medical University of South Carolina
- Primary completion
- Aug 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Creatinine Levels |
0.5; 0.55 | — |
| PRIMARY Change in Urine Output |
1353; 731 | — |
| SECONDARY Count of Participants Who Needed Diuretics Postoperatively |
4; 1 | — |
| SECONDARY Count of Patient Who Need Vasopressers in the Perioperative Period |
3; 4 | — |
Summary
The purpose of this study is evaluate the medication vasopressin for its ability to preserve kidney function in patients undergoing liver transplantation.
Eligibility Criteria
Inclusion Criteria
- > 18 years of age
- undergoing liver transplant
- ability to provide informed consent. If patient is unable to give informed consent i.e. hepatic encephalopathy, consent may be obtained from the patient's legally authorized representative
Exclusion Criteria
- < 18 years of age
- renal failure
Data sourced from ClinicalTrials.gov (NCT00886262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.